INMB May 2024 12.500 call
| Previous close | 0.2500 |
| Open | 0.3000 |
| Bid | 0.2000 |
| Ask | 0.3500 |
| Strike | 12.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.2000 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 379 |
GlobeNewswireINmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to share an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro™ for treatment of Alzheimer’s Disease (AD) for more than three years under the Australian compassionate use program known as the Special A
- GlobeNewswire
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce the successful completion of the first cohort in the trial. Foll
Simply Wall St.INmune Bio Independent Director Acquires 80% More Stock
Potential INmune Bio, Inc. ( NASDAQ:INMB ) shareholders may wish to note that the Independent Director, Scott Juda...
